Alpha 2.0
Login Register
» Authors » Charlotte Levin Tykjaer Jorgensen

Charlotte Levin Tykjaer Jorgensen

Explore the profile of Charlotte Levin Tykjaer Jorgensen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 125
Followers 0
Related Specialties
Oncology
Biochemistry
Molecular Biology
Top 10 Co-Authors
Kristina Aaltonen
Lisa Ryden
Par-Ola Bendahl
Anna-Maria Larsson
Carina Forsare
Sara Jansson
Marten Ferno
Christina Bjerre
Nils Brunner
Eva Balslev
Published In
BMC Cancer
Breast Cancer Res Treat
Cancers (Basel)
Breast Cancer Res
Int J Mol Sci
Affiliations
Soon will be listed here.
Recent Articles
1.
PAM50 Intrinsic Subtype Profiles in Primary and Metastatic Breast Cancer Show a Significant Shift toward More Aggressive Subtypes with Prognostic Implications
Jorgensen C, Larsson A, Forsare C, Aaltonen K, Jansson S, Bradshaw R, et al.
Cancers (Basel) . 2021 Apr; 13(7). PMID: 33808271
Background: PAM50 breast cancer intrinsic subtyping adds prognostic information in early breast cancer; however, the role in metastatic disease is unclear. We aimed to identify PAM50 subtypes in primary tumors...
2.
The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast-Long-Term Prognostic Significance
Narbe U, Bendahl P, Aaltonen K, Ferno M, Forsare C, Jorgensen C, et al.
Cells . 2020 Jul; 9(7). PMID: 32709042
Background: Invasive lobular carcinoma (ILC) has distinguishing features when compared to invasive ductal carcinoma of no special type (NST). In this study, we explored the distributional and prognostic characteristics of...
3.
Evolution of Estrogen Receptor Status from Primary Tumors to Metastasis and Serially Collected Circulating Tumor Cells
Forsare C, Bendahl P, Moberg E, Jorgensen C, Jansson S, Larsson A, et al.
Int J Mol Sci . 2020 Apr; 21(8). PMID: 32326116
Background: The estrogen receptor (ER) can change expression between primary tumor (PT) and distant metastasis (DM) in breast cancer. A tissue biopsy reflects a momentary state at one location, whereas...
4.
Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
Jorgensen C, Forsare C, Bendahl P, Falck A, Ferno M, Lovgren K, et al.
Breast Cancer Res Treat . 2020 Apr; 181(2):369-381. PMID: 32300922
Purpose: The study aimed to investigate expression of epithelial-to-mesenchymal transition (EMT)-related proteins and phenotypes during breast cancer progression and to relate this to patient outcome. Methods: Protein expression patterns of...
5.
Serial evaluation of serum thymidine kinase activity is prognostic in women with newly diagnosed metastatic breast cancer
Larsson A, Bendahl P, Aaltonen K, Jansson S, Forsare C, Bergqvist M, et al.
Sci Rep . 2020 Mar; 10(1):4484. PMID: 32161278
The rapid development of new therapies in metastatic breast cancer (MBC), entails a need for improved prognostic and monitoring tools. Thymidine kinase 1 (TK1) is involved in DNA synthesis and...
6.
Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
Larsson A, Jansson S, Bendahl P, Jorgensen C, Loman N, Graffman C, et al.
Breast Cancer Res . 2018 Jun; 20(1):48. PMID: 29884204
Background: Circulating tumor cells (CTCs) carry independent prognostic information in patients with metastatic breast cancer (MBC) on different lines of therapy. Moreover, CTC clusters are suggested to add prognostic information...
7.
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group
Jorgensen C, Bjerre C, Ejlertsen B, Bjerre K, Balslev E, Bartels A, et al.
BMC Cancer . 2014 Jun; 14:360. PMID: 24884504
Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has anti-apoptotic functions, which may protect TIMP-1 positive cancer cells from the effects of chemotherapy such as docetaxel and gemcitabine. The purpose of the...